Can positron emission tomography with (18F)-fluorodeoxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity? - Spaepen,K.; Stroobants,S.; Dupont,P.; Thomas,J.; Vandenberghe,P.; Balzarini,J. (Brit J Haem, 2001)